171 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
15 May 24
Adaptimmune Reports Q1 2024 Financial and Business Updates
7:39am
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
15 May 24
Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital
7:14am
Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
12 Apr 24
Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader sarcoma franchise
8:05am
the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties
8-K
EX-99.1
r18i0q4kyd4rsp44cne
6 Mar 24
Adaptimmune Reports Q4 /Full Year 2023 Financial Results and Business Updates
7:05am
8-K
EX-99.1
uhgjs3k k8g2t3ur
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
EX-99.1
uloxqusee
31 Jan 24
Other Events
5:07pm
8-K
EX-99.1
l4jt 6g0u
4 Jan 24
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million – Presentation at JP Morgan Healthcare Conference
7:46am
8-K
EX-99.1
qmoeh0u 32c
6 Dec 23
Other Events
7:13am
8-K
EX-99.1
6gped3r 8x3t3mig
8 Nov 23
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:37am
8-K
EX-99.1
ljmld8gb5
31 Oct 23
Adaptimmune Reports Positive Data with Lete-cel1 from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
8:07am
8-K
EX-99.1
v8e5 2yzool2wtxwdgx
9 Aug 23
Adaptimmune Reports Second Quarter Financial Results and Business Update
7:42am
8-K
EX-99.1
opq8adl fs3t2ekcq
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.1
x5e78ikx4ml8don2e
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
425
oqzo3uk j6b1mknf8ook
30 May 23
Business combination disclosure
4:21pm